


Long-term Results From an Open-label Extension Study of Atacicept for the Treatment of IgA Nephropathy



Conclusion: Atacicept was well tolerated over the duration of the study. Atacicept treatment reduced Gd-IgA1, hematuria, and UPCR with stabilization of eGFR through 96 weeks.

Barratt, J., et al. "Long-term Results From an Open-label Extension Study." *Journal of the American Society of Nephrology*, vol. 99, no. 99, 2024.

https://journals.lww.com/jasn/fulltext/9900/long_term_results_from_an_open_label_extension.458.aspx

Visual Abstract by:
Denisse Arellano
@deniise_am